Stitch Fix Inc
Change company Symbol lookup
Select an option...
SFIX Stitch Fix Inc
PDD Pinduoduo Inc
VIV Telefonica Brasil SA
EXPR Express Inc
KVSC Khosla Ventures Acquisition III Co
BWV Blue Water Vaccines Inc
ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund
LGO Largo Inc
ONTO Onto Innovation Inc
OFED Oconee Federal Financial Corp
Go

Consumer Discretionary : Internet & Direct Marketing Retail | Small Cap Value
Company profile

Stitch Fix, Inc. is an online personalized styling service company. The Company operates primarily in the United States and United Kingdom. The Company combines the human touch of stylists with the precision of advanced data science to make online personal styling accessible to everyone. The Company serves its clients in categories, such as women's, petite, maternity, men's, kids, and plus apparel, as well as shoes and accessories. The Company leverages its data science through a custom-built, Web-based styling application that provides recommendations to its stylists from its selection of merchandise. It also gathers a range of merchandise data, such as inseam, pocket shape, silhouette, and fit. Its clients can engage in receiving a personalized shipment of items informed by its algorithms and sent by a Stitch Fix stylist (a Fix). Its clients can purchase directly from its Website or mobile app based on a personalized assortment of outfit and item recommendations.

Closing Price
$4.94
Day's Change
0.52 (11.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.98
Day's Low
4.33
Volume
(Above Average)
Volume:
2,982,170

10-day average volume:
2,683,509
2,982,170

Novavax to Participate in Jefferies London Healthcare Conference

4:02 pm ET November 14, 2022 (PR Newswire) Print

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the Jefferies London Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Conference Details:
Fireside Chat
Date:                 Wednesday, November 16, 2022
Time:                 8:35 - 9:05 a.m. Greenwich Mean Time (GMT)
Location:             London
Moderator:            Roger Song, M.D., CFA
Novavax participants: Filip Dubovsky, M.D., Executive Vice President, Chief Medical Officer
                      and John J. Trizzino, Executive Vice President, Chief Commercial
                      Officer and Chief Business Officer
Conference
Event:                Investor Meetings
Date:                 Wednesday, November 16, 2022 - Thursday, November 17, 2022

RecordingsA replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.comfor 90 days from the date of the conference.

About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional populations and indications such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.comand connect with us on LinkedIn.

Contacts: InvestorsErika Schultz | 240-268-2022ir@novavax.com

MediaAli Chartan or Giovanna Chandler | 240-709-5563media@novavax.com

https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

https://c212.net/c/img/favicon.png?sn=PH35728&sd=2022-11-14

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-london-healthcare-conference-301677468.html

SOURCE Novavax, Inc.

https://rt.newswire.ca/rt.gif?NewsItemId=PH35728&Transmission_Id=202211141602PR_NEWS_USPR_____PH35728&DateId=20221114

comtex tracking

COMTEX_418861998/1005/2022-11-14T16:02:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.